Corona Vaccine Tracker: Oxford-AstraZeneca vaccine to be first available in India; Human trials of 29 vaccines are going on

Posted on 20th Aug 2020 by rohit kumar

Expectations regarding the vaccine have also increased amidst increasing cases of coronaviruses. According to the World Health Organization (WHO) vaccine tracker, there are now 29 vaccines undergoing human trials. At the same time, 138 vaccines are undergoing pre-clinical testing. China's state-owned Sinofarm claims that its vaccine will come on the market by December.

 

Indigenous vaccine manufacturers Bharat Biotech-ICMR and Zydus Cadila Vaccine Phase-2 have entered the human trials. At the same time, there are reports that KoviShield made of Oxford-AstraZeneca will be available in India first. Serum Institute of India has obtained permission for Phase-2 and Phase-3 Human Trials in India.

 

First of all, China's vaccine ... Sinopharm vaccine will be available in December

 

The vaccine produced by Canon Biologics in China has received a patent. The document, published on the website of China's National Intellectual Property Administration, claimed that the vaccine could be mass-produced in an outbreak.

 

The patent was issued on August 11, according to a report by the Chinese state-run People's Daily. On the same day, Russian President Vladimir Putin announced the registration of the Russian vaccine "Sputnik-V".

 

At the same time, the vaccine being developed by the Wuhan Institute of Biological Products of China will be commercially available in December. The head of Sinopharm, the company making it, said that phase-3 trials of the vaccine are moving in the right direction.

 

Sinopharm vaccine will come to 1,000 yuan i.e. about 10,800 rupees. It is of two doses. Which will be given in a gap of 28 days. One dose of this gives protection for up to 97% against the corona, while protection is 100% when the second dose is applied.

 

This vaccine from Sinopharm has been successful in Phase-1/2 trials. Its phase-3 trials are going on. Tests so far have shown that strong antibody response has been found after applying the vaccine.

 

What is happening to the indigenous vaccine?

 

India has completed Biotech Kovacine and Zydus Cadila Vaccine Phase-1. Its phase-2 human trials have started. According to the WHO tracker, work is going on at a fast pace. But the vaccine will come in the market only next year.

 

At the same time, the Serum Institute of India has obtained permission for the Phase-2 and Phase-3 trials of the Kovyshield vaccine of Oxford-AstraZeneca in India. For this, hospitals have appealed to Volunteers to come forward.

However, the good thing is that its Phase-3 has already started in the UK, US, and Brazil. That is, even if we do not get the results of trials, the Serum Institute will start making it. This vaccine will be available in India for Rs 225.

 

WHO'S DOING?

 

WHO has launched the Kovacs Global Vaccine Facility Program. It has been designed by the WHO to raise funds from rich countries and non-profits. So that two billion effective vaccines can be delivered, supporting the worldwide vaccine development program.

 

The deadline of 31 August has been set to join this program. The Gavi Vaccine Alliance and the Coalition for Epidemic Preparedness Innovations are also associated with the program along with WHO.

 

Kovacs is part of a larger program, called the Access to Covid-19 Tools (ACT) accelerator. It ensures vaccines, treatment, diagnostic tests, and other healthcare resources to fight epidemics.

 

The United States, the UK, Japan, and the European Union have spent billions of dollars dealing with vaccine manufacturers. The United States alone has developed $ 11 billion in deals to develop and deliver the vaccine.